Holy transmission, bat-to-man {#cesec10}
=============================

Bats, thought to be the ancestral hosts of [coronaviruses](https://doi.org/10.1038/s41598-020-64264-1){#interrefs10} that cause disease in people, do not themselves become ill when infected, and nobody knows why. Findings from an in-vitro study show that the Middle East respiratory syndrome coronavirus persists in bat cells thanks to a delicate immunological interplay between cell and virus. Bat cells seem able to upregulate type I interferon, which suppresses viral replication to avoids the cell death seen in infected human cells. The virus also adapts by rapidly mutating a specific gene in the viral open reading frame 5. The researchers posit that stress---for instance, from habitat loss or wet markets---can disturb this regulatory balance and cause spill-over into other species.

SARS-CoV-2 insights {#cesec20}
===================

An analysis of severe acute respiratory syndrome coronavirus 2 ([SARS-CoV-2](https://doi.org/10.1016/j.meegid.2020.104351){#interrefs20}) genomes from more that 7500 isolates collected around the word has identified almost 200 mutations in the virus that have happened independently and on multiple occasions. These recurrent mutations might suggest ongoing adaptation to human hosts. Other areas of the genome have stayed stable, suggesting the potential of targets for treatments or vaccines. A phylogenetic analysis shows that, in the worst-hit countries, genetic diversity is similar to the global level, indicating that the virus has entered these countries on multiple occasions, rather than through just one index case.

SARS-CoV-2 antigen test? {#cesec30}
========================

A rapid antigen test has shown promise in detecting SARS-CoV-2 in nasopharyngeal samples from 328 people with suspected infections. The COVID-19 Ag Respi-Strip (Coris BioConcept; Gembloux, Belgium), which gives results in 15 minutes, had a sensitivity to correctly identify positive results of 57·6%, and had near perfect specificity, correctly identifying negative samples with an accuracy of 99·5%. The immunochromatographic [test](https://doi.org/10.3389/fmed.2020.00225){#interrefs30} detects the presence of the SARS-CoV-2 nucleocapsid protein, and because it is cheaper and less technically demanding than RT-PCR, researchers believe it could help limit the spread of the virus by quickly identifying suspected cases for quarantine, especially in resource-poor areas.

Human antibody {#cesec40}
==============

Findings from an in-vitro study in monkey cells suggest that a team of European researchers have identified a human monoclonal [antibody](https://doi.org/10.1038/s41467-020-16256-y){#interrefs40} that blocks SARS-CoV-2 infection. The team had previously worked on antibodies targeting the SARS-CoV from 2002/2003 and identified the antibody 47D11, which their most recent study shows can cross neutralize both viruses. The antibody does so by targeting a conserved region on the trimeric spike glycoprotein involved in cell entry. A treatment based on 47D11 might thus hold potential for future outbreaks of coronaviruses, but further work is needed to better understand how the antibody works. The fact that the antibody is fully human bodes well for speedy progress into human trials.

Fight parasite with parasite {#cesec50}
============================

Researchers have identified a microbe, [Microsporidia](https://doi.org/10.1038/s41467-020-16121-y){#interrefs50} MB, that protects *Anopheles arabiensis* mosquitoes from *Plasmodium falciparum* infection. The study, done near Lake Victoria in Kenya, found microsporidia infections in roughly 5% of sampled insects, none of which had Plasmodium infection. Further laboratory studies confirmed that the microsporidia gave complete protection from Plasmodium. It is still unclear how the microbe confers protection. It might prime the insects\' immune system or interfere with metabolism in such a way that the parasites can\'t survive. Microsporidia MB infection does not determine any fitness cost for the mosquitoes, which makes it a promising candidate for use in biological malaria control.

BCG potential {#cesec60}
=============

Widespread [BCG vaccination](https://doi.org/10.1126/scitranslmed.aax4517){#interrefs60} within a few days of birth could save close to a million newborn lives a year, say researchers, but not from tuberculosis, the disease it was designed to vaccinate against. Findings from a 5-year cohort study in Guinea-Bissau and The Gambia show that BCG vaccination within 3 days of birth gives substantial protection from sepsis, the cause of three quarters of all deaths within the first week of life. The researchers confirmed the finding in a mouse model of neonatal polymicrobial sepsis, in which they detected a rapid and protective increase in neutrophils, or emergency granulopoiesis, a finding they later validated in blood samples from children from The Gambia and Guinea-Bissau.

Modellers: it is good to talk {#cesec70}
=============================

A team of researchers from Australia, China, the UK, and the USA, has proposed a process for harnessing multiple disease [models](https://doi.org/10.1126/science.abb9934){#interrefs70} to help give clearer recommendations to policy makers. The process has three main steps: each team is first set a specific scenario to model (eg, the lifting of social isolation measures for COVID-19), they then meet to discuss their models and, finally, refine each of their models on the basis of the learning from group discussions. While helping each team make more robust models, the process can also guide future research priorities by identifying the most important gaps in knowledge.
